CI
REGN icon

Conning Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Conning Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$356K Sell
461
-70
-13% -$53.6K 0.01% 240
2025
Q4 		$410K Buy
531
+11
+2% +$7.47K 0.01% 244
2025
Q3 		$292K Hold
520
– – 0.01% 302
2025
Q2 		$273K Sell
520
-28
-5% -$15.6K 0.01% 304
2025
Q1 		$348K Sell
548
-3
-0.5% -$2.06K 0.01% 275
2024
Q4 		$392K Sell
551
-73
-12% -$61.3K 0.01% 259
2024
Q3 		$656K Sell
624
-11
-2% -$12.2K 0.02% 207
2024
Q2 		$667K Buy
635
+16
+3% +$15.5K 0.02% 200
2024
Q1 		$596K Buy
619
+47
+8% +$44.7K 0.02% 210
2023
Q4 		$502K Buy
572
+2
+0.4% +$1.65K 0.02% 214
2023
Q3 		$469K Sell
570
-9
-2% -$7.07K 0.02% 217
2023
Q2 		$416K Sell
579
-70
-11% -$54K 0.01% 242
2023
Q1 		$533K Sell
649
-7
-1% -$5.28K 0.02% 222
2022
Q4 		$473K Sell
656
-4
-0.6% -$2.95K 0.02% 244
2022
Q3 		$455K Sell
660
-34
-5% -$21.4K 0.02% 234
2022
Q2 		$410K Sell
694
-4
-0.6% -$2.6K 0.01% 265
2022
Q1 		$487K Sell
698
-114
-14% -$72.1K 0.01% 262
2021
Q4 		$513K Sell
812
-17
-2% -$10.5K 0.01% 249
2021
Q3 		$502K Sell
829
-311
-27% -$193K 0.01% 265
2021
Q2 		$637K Sell
1,140
-125
-10% -$63.3K 0.02% 241
2021
Q1 		$599K Sell
1,265
-101
-7% -$49.2K 0.02% 242
2020
Q4 		$660K Buy
1,366
+151
+12% +$81.5K 0.02% 238
2020
Q3 		$680K Buy
1,215
+35
+3% +$21.2K 0.02% 230
2020
Q2 		$736K Buy
1,180
+131
+12% +$74.4K 0.03% 217
2020
Q1 		$512K Sell
1,049
-2
-0.2% -$825 0.02% 246
2019
Q4 		$395K Buy
1,051
+80
+8% +$26.9K 0.01% 332
2019
Q3 		$269K Sell
971
-129
-12% -$38.2K 0.01% 418
2019
Q2 		$344K Sell
1,100
-210
-16% -$69.9K 0.01% 371
2019
Q1 		$538K Sell
1,310
-10
-0.8% -$4.12K 0.02% 332
2018
Q4 		$493K Sell
1,320
-400
-23% -$146K 0.02% 331
2018
Q3 		$695K Sell
1,720
-260
-13% -$99K 0.02% 317
2018
Q2 		$683K Sell
1,980
-100
-5% -$31.3K 0.02% 331
2018
Q1 		$716K Sell
2,080
-40
-2% -$13.9K 0.02% 317
2017
Q4 		$797K Buy
2,120
+10
+0.5% +$4.05K 0.03% 317
2017
Q3 		$943K Hold
2,110
– – 0.03% 283
2017
Q2 		$1.04M Hold
2,110
– – 0.04% 272
2017
Q1 		$818K Sell
2,110
-10
-0.5% -$3.71K 0.03% 301
2016
Q4 		$778K Buy
2,120
+270
+15% +$103K 0.03% 306
2016
Q3 		$744K Sell
1,850
-100
-5% -$40.1K 0.03% 307
2016
Q2 		$681K Sell
1,950
-90
-4% -$34.7K 0.03% 318
2016
Q1 		$735K Hold
2,040
– – 0.03% 298
2015
Q4 		$1.11M Sell
2,040
-100
-5% -$54.2K 0.05% 246
2015
Q3 		$995K Sell
2,140
-110
-5% -$59.1K 0.04% 250
2015
Q2 		$1.15M Sell
2,250
-10
-0.4% -$4.88K 0.05% 247
2015
Q1 		$1.02M Buy
2,260
+10
+0.4% +$4.24K 0.04% 247
2014
Q4 		$923K Sell
2,250
-10
-0.4% -$3.93K 0.05% 259
2014
Q3 		$815K Buy
2,260
+250
+12% +$83.8K 0.04% 275
2014
Q2 		$568K Sell
2,010
-100
-5% -$29.6K 0.03% 340
2014
Q1 		$634K Buy
2,110
+730
+53% +$225K 0.04% 316
2013
Q4 		$380K Buy
1,380
+410
+42% +$118K 0.02% 398
2013
Q3 		$303K Buy
+970
New +$255K 0.02% 394

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Conning Inc's REGN Position: Q1 2026 in Review

Conning Inc reduced its Regeneron Pharmaceuticals (REGN) stake by 13% in Q1 2026, selling an estimated $53.6K and leaving 461 shares worth $356K. The position accounts for 0.01% of the portfolio, ranked #240.

Conning Inc first reported a position in REGN in Q3 2013 and has held it in 51 quarters since. The position peaked at $1.15M in Q2 2015. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Conning Inc held 461 shares of Regeneron Pharmaceuticals worth $356K as of Q1 2026.
  • Conning Inc sold 70 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $53.6K.
  • Regeneron Pharmaceuticals made up 0.01% of Conning Inc's portfolio in Q1 2026, its #240 holding.
  • Conning Inc first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
  • Conning Inc's Regeneron Pharmaceuticals position peaked at $1.15M in Q2 2015.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Conning Inc's 13F filing for Q1 2026, filed 30 Apr 2026.